Natural Killer (NK)I.1 + (NK1) T cells are a specialized subset of ti/[3 T cells that coexpress surface receptors that are normally associated with the NK cell lineage of the innate immune system. On recognition of the conserved, major histocompatibility complex class I-like CD1 molecule, these cells are able to release explosive bursts of interleukin 4 (IL-4), a cytokine that promotes the T helper type 2 (Th2) effector class of an immune response. A unique feature of their T cell receptor (TCIL) repertoire is the expression of an invariant TCR ot chain, Vcl14-Jix281, and of a restricted but polyclonal set of V[3 gene families, V[38, V~7, and V[32. Here, we show that transgenic expression of this TCR ot chain during thymic development is sufficient information to bias the differentiation of mainstream thymocytes towards the NK1 developmental pathway. It markedly increases the frequency of cells with the NK1 pattern of T cell differentiation and also has drastic consequences for the selection of the V[3 repertoire. Transgenic CD4 cells exhibited a 10-100-fold increase in IL-4 production on mitogen stimulation in vitro and in vivo, and baseline levels of the Th2-controUed serum immunoglobulin isotypes, IgE and IgG1, were also selectively elevated in vivo.
U
'nlike mainstream el/13 T cells, NK1 T cells acquire, during thymic development, the unusual property of secreting IL-4 on primary stimulation, and of expressing receptors normally associated with the NK lineage such as NKI.1 (reviewed in references 1-3). Their positively selecting ligand appears to be the conserved MHC class I-like molecule CDI, expressed on cortical thymocytes (4, 5) rather than the polymorphic MHC restriction elements expressed on thymic epithelium (6) (7) (8) (9) , and their resulting TCP,. repertoire is severely limited. More than 85% of NK1 T cells express an invariant TCR ot chain, VoH4-Jot281 (10) , and a limited set of TCIL V[3 chains (V~8,7 and 2) (8, (11) (12) (13) (14) (15) which, together, generate specificity for CD1 in the apparent absence of foreign antigens (4, 5) . NK1 T cells are found among mature HSN ~ thymocytes as single positive CD4+8 -(the main IL-4 producer) and double-negative (DN) 1 CD4-8-cells, but they are remarkably absent from the CD8+4 -subset (8, 10) . Humans have a similar set of T cells that use the invariant TCR ot 1Abbreviations used in this paper: DN, double negative; EAE, experimental allergic encephalomyelitis. chain Vc124-JotQ, and V[311, the homolognes to mouse Vct14-J0t281 and V [38, and humans also express a homologous CD1 ligand, the CDld molecule (10, 16, 17) . Thus, NK1 T cells seem to belong to an ancient cell type, straddling the innate and adaptive immune systems, whose semiinvariant ci/[3 TCRs and conserved CD1 ligand predate the speciation of mouse and man.
Their high frequency in peripheral lymphoid tissues (0.5-1% of spleen and LN cells), and their ability to explosively release IL-4 in response to CD1 induction on APC might strongly shift the effector class of immune responses towards Th2 (4, 18, 19) . Indeed, NK1 T cells are essential for generating the polyclonal Th2 and IgE response that is induced upon intravenous injection of goat anti-mouse IgD antibodies (20) . This can have profound consequences on subsequent immunizations. For example, preimmunization with myelin basic protein coupled to mouse anti-rat IgD antibody induced myelin basic protein~pecific Th2 cells and protected rats from subsequent attempts to induce experimental allergic encephalomyelitis (EAE) (21) . In addition, NK1 T cells are severely deficient in SJL (22) and nonobese diabetic (23) mice, two strains which are conspicuously susceptible to Thl-mediated autoimmune diseases, EAE and diabetes, respectively. This raises the possibil-ity that the NK1 T ceils normally function to suppress or deviate tissue-destructive Thl responses.
Since CD1 is constitutively expressed by cortical doublepositive CD4+8 + thymocytes, the cell type that appears to positively select the NK1 T ceils (5), it is available for recognition by developing thymocytes that express a CD1-specific TCR.. We therefore used a transgenic approach to investigate the consequences of expression of a Vet14-Jet281 + TCR on thymocyte development. We generated transgenic mice expressing the rearranged Vet14-Jet281 transgene under the control of an endogenous Vet promoter, the Vet11 promoter, and the Ig enhancer (24) . The TCR et chain transgene was tested alone, without a TCR [3 chain transgene, to determine the extent to which it determines the NK1 developmental fate of mainstream thymocytes. Our results indicate that expression of the canonical Vet14-Jet281 + TCIZ et chain has drastic consequences on the selection of TCR. [3 chains of the V[38 and V[~7 families as well as on the NK1 differentiation and function of thymocytes. In addition, transgenic mice exhibited a major increase in their potential to produce IL-4, as well as in their baseline levels of Th2-controlled isotypes, in particular IgE.
Materials and Methods
Transgenic and Mutant Mice. Vot14-Jot281 and Vot8-Jot37 gene segments were PCP.-amplified from genomic DNA of the CD1 specific T cell hybridoma DN32D3 (10) and the IAa/rabbit Igspecific T cell clone CDC35, respectively (25) , and cloned into a TCR ci shuttle vector containing the Vodl endogenous promoter and the Ig enhancer as described (24) . Linearized constructs were injected into B6 fertilized eggs, and transgenic founders screened by tail DNA PCR with specific primers. C57BL/6, and C57BL/6.Ctx null mice (TCR ot knockout [26] , backcrossed nine times to B6) were purchased from The Jackson Laboratory (Bar Harbor, ME) or Taconic Farms, Inc. (Germantown, NY) and raised under specific pathogen-free conditions. Voe14-Jot281 transgenic mice with a homozygous nmtation of the endogenous Cot genes were generated by crossing transgenics to Cot mutants, selecting for offsprings that expressed oe/13 TCR high blood cells without using endogenous Vot gene products (detected using a combination of anti-Vo~2, Vc~8 and Vctl I antibodies).
FACS ~ Analysis~Sorting. Thymocyte and spleen cell suspensions were three-or four-color stained using combinations of antibodies conjugated to tricolor (anti-CD4; Caltag Laboratories, South San Francisco, CA), red 613 (anti-CDS; GIBCO BKL Life Technologies, Gaithersburg, MD), FITC, and PE (or biotin followed by PE-conjugated streptavidin bodies plus low toxicity rabbit complement (Cedarlane Laboratories Ltd., Hornby, Canada) for 45 mn at 37~ in a final volume of a 1:1 mixture of RPMI and Click's media enriched with 10% heat inactivated FCS, 5 • 10 -5 M 2-ME, penicillin, streptomycin, and gentamycin (complete medium), in a 96-U-bottomed well microplate. Cytokines released in the supernatant were measured 48 h later using the IL-4-sensitive CT4.S line and the IFN-'y sandwich ELISA as described (27) .
For in vivo stimulation with anti-CD3, mice were injected i.v. with 1 ~g 2Cll anti-CD3 antibody, and spleen cells removed 90 rain later and cultured, without further stimulation, as described (18), at a density of 10 v cells in 2 ml of complete medium for 2 h to measure cytokine release in the culture supematant.
Serum Ig Isotype Levels. Serum levels oflg isotypes were measured by standard sandwich ELISA (IgA, M, G1, G2a, G2b, G3; Southern Biotechnology, Birmingham, AL; IgE; PharMingen). The average level of each isotype in normal mice was set up arbitrarily at 100 U/ml.
Results

Altered T Cell Development and V~8 Usage in Vee14-Joe281
Transgenic Mice. Four distinct founder lines of mice expressing the Vcl14-Joe281 transgene were produced in a C57BL/6 background, as well as a control line expressing Vot8-Jot37, a TCR ot chain not associated with NK1 T cells (25) . Because there exists no antibody specific for Veil4, surface expression of the Vod4-Jot281 ct chain was confirmed by showing that transgene expression rescued T cell development in TC1< C(x null mice (Fig. 1 , third column). Transgene expression was also evident from the phenotype described below.
A common feature of all four V(x14-Jcx281 transgeneexpressing lines was a fivefold reduction in thymus size, affecting mainly double-positive thymocytes (Fig. 1) . This size reduction did not occur in mice expressing the control Vot8-Jot37 transgene, suggesting that a bypass of the double-positive stage of thymic development (28, 29) or a deletion at that stage had occurred as a consequence of the Vcx14-Jot281 TCI< specificity. A 30% reduction of the number ofT cells was also observed in the spleen of Vcil4-Jot281 transgenics together with a marked increase in DN (x/~ T cells (Fig. 1) .
In normal mice, both the CD4 and the DN NK1 T cells use mainly Vl38, Vl37, and Vl32 TCI< 13 chains. We have suggested that, coupled with Vod4-Jot281, these 13 chains allow for high affinity CD1 binding. Indeed, this affinity seems to be high enough that the additional binding contributed by the CD8 coreceptor induces deletion. Thus, normal mice do not have CD8 cells expressing these TCP, s and the forced, transgenic expression of CD8 induces deletion of the entire Vod4-J0r + NK1 T cell subset (8, 10) . Figs. 2 and 3 show that the CD8 single-positive compartment in transgenic mice was selectively depleted of cells expressing the V[38 and V137 TCR. 13 chains most commonly used by NK1 T cells whereas control V[36 + cells were not deleted (Figs. 2 and 3 ). The extent of this deletion indicated therefore that a majority of Vl38 and Vl37 TCR. sult demonstrates first that the bias in V[38 and V~7 usage among normal NK1 T cells is not the result of a preferential physical pairing o f these T C R [3 chains with the Vci14-Jix281 TCR. ix chain, and therefore suggests that these TCR. 13 chains are selected because they contribute affinity to the CD1 ligand. Second, it reenforces the hypothesis that the N K 1 -D N T cells observed in "conventional" TCP. transgenic mice result from the enforced (transgenic) early expression of an ix/J3 T C R in a separate lineage that does not usually express it, possibly a y / 8 committed precursor, which follows different rules of selection and differentiation (30) (31) (32) . Interestingly, a population of CD44 high IL21<[3 + NK1.1 + double-negative T cells has recently been observed in an anti-K b ix/J3 TCP. transgenic system (33) . As in the anti-CD1 system, the NK1 surface phenotype was ascribed to a higher than usual affinity (CD8-independent) of the anti-K b transgenic ix/13 TCP. for its thymic ligand during positive selection. Another transgenic line expressing an anti-K b TCR. of lower affinity (CDS-dependent) only produced N K 1 -D N T cells.
Endogenous T C R ix Chain Usage by Transgenic T Cells.
Although we could not directly monitor the frequency of cells expressing the transgenic ix chain due to the lack of an anti-Vix14 antibody, FACS | staining for Vix2 (Fig. 2) , as well as Vix8 and Vix11 (not shown), which altogether are expressed by "~20% o f normal T cells, indicated that the transgenic mice contained 25% fewer CD4 T cells express- (Fig. 1) . Although this might be expected from the original association of Vix14-Jix281 + TCIks and D N NK1 T cells (10) , it has also been observed that most TCP. transgenic mice, irrespective of their TCR. specificity, generate a sizable population of D N T cells (30) (31) (32) . Indeed, our control Vix8 transgenics also harbored a higher frequency of D N ix/[3 T cells (which expressed the Vix8 transgenic chain [not shown]), although this frequency was two times lower than in Vix14-Jix281 transgenics (Fig. 1) . Importantly however, the majority of Vix8 transgenic D N cells did not express activation/NK receptors (Fig. 1) , nor did they display a biased usage o f V[3 gene products (not shown), implying that these unique features are the consequence of particular TCI< specificities. A closer examination of the Vix14-Jix281 transgenic D N cells revealed that they could in fact be separated into two distinct subpopulations o f approximately equal size, according to their expression of activation/NK receptors (Fig. 5) . The CD44hig h (NKI.1 high) had a markedly biased usage o f V[38 and V[37 TCR. [3 chains whereas the CD44 l~ subset did not. This could be observed in mice with a homozygous mutation of their T C R Cix genes (Fig. 5) , indicating that expression of the Vix14-Jix281 TCI< ix chain can lead to both VI3-biased NK1 + and V [3- Figure 6 . Increased frequencies of Th2-controUed lg isotypes in Vcx14-Jcx281 transgenic mice. Serum levels of Ig isotypes were measured by standard sandwich ELISA in 3-5-too-old Vet14-J~t281 transgenic mice, and littermate controls. Six to eight individual nfice were examined for each of the four transgenic lines and all data were pooled, as there was no detectable difference between the different lines. The average level of each isotype in normal mice is set up arbitrarily at 100 U/ml. IgE average levels in Vot14-Jix281 transgenic mice are increased sixfold above controls (P <0.001) and IgGI are increased twofold (P <0.01).
ing endogenous ix chains than control mice. This suggested that at least 25% of CD4 T cells expressed the transgenic ix chain on their surface. Conversely, no reduction of endogenous ix chain expression was observed on CD8 cells, again supporting the view that CD8 cells expressing high surface levels of the transgenic V0t14-Jix281 ix chain were deleted and that the remaining CD8 cells were those which expressed an endogenous ix chain capable of outcompeting Vix14-Jix281 for pairing with the TCP,. [3 chain. Indeed, mice expressing the Vod4-Jix281 transgene in a Cix-null background exhibited a marked reduction of CD8 cells (Fig.l) , whereas their CD4 cells contained an even higher frequency of V[38 + and V[37 + TCP, s (Fig. 2) .
Biased IL-4 Production by Transgenic T Cells. To test whether
transgenic expression of Vix14-Jix281 also induced an increase in the functional potential to produce IL-4, we measured the levels of cytokines released upon TCR crosslinking with anti-CD3 antibody. In vitro, transgenic T cells secreted ~60 times more IL-4 and 4 times less IFN-y than transgene-negative littermates (Table 1) or than Vo~8-Jix37 transgenic controls (not shown). As in normal mice, the increased IL-4 secretion was mainly contributed by CD4 + T cells (Table 1) . In vivo, we measured the rapid release oflL-4 that is observed within 1 h of TCR. engagement, a specific feature of NK1 T cells (18) . Table 1 shows that Vix14-Jix281 transgenic spleen cells release >10-fold more early IL-4 than controls. Identical results for the in vitro and in vivo experiments were obtained in all four Vix14-Jix281 transgenic founder lines tested, as well as in TCP-. Cix-null mice expressing the Vcx14-Jix281 transgene.
Increased Baseline Levels of Th2-controlted Ig lsotypes. If NK1
T cells are effective regulators of Thl/Th2 differentiation in normal conditions, one would expect the transgenic mice to express a specific increase of thebaseline levels of the serum Ig isotypes that are promoted by IL-4, induced as a result of ongoing immune responses to environmental antigens. As shown in Fig. 6 , Vix14-Jo~281 transgenic mice of all founder lines had a selective and conspicuous increase of IgE (sixfold above controls on average) and IgG1 (twofold above controls), the two Th2-controlled isotypes (19, 34) . The blood levels of other isotypes including IgM, IgA, IgG2a, IgG2b, and IgG3 were unchanged. Control Vo~8-Jix37 transgenics, raised under the same specific pathogenfree conditions, did not exhibit changes in IgE or IgG1 levels (not shown).
Discussion
Our results indicate that expression by mainstream thymocytes of the NK1 T cell Vot14-Jot281 TCR ix chain alone has drastic consequences on the positive and negative selection of V[3 chains in CD4 and CD8 cells, respectively, mimicking the CDl-specific Tell repertoire expressed on normal NK1 T ceils. The extent of the depletion of V[38-and V[37-positive CD8 cells indicate that Vix14-Jix281 can pair with a very large proportion of TCR. [3 chains using the V[38 and V[37 gene families (which are used by 30-50% of the T cell population in most mouse strains), to form a TCR with affinity for CD1, and that the overall avidity of interaction is increased by the CD8 coreceptor. The results imply that, from a developmental (and evolutionary) perspective, one may consider that expression of the Vix14-Jix281 + TCI< ix chain alone is sufficient information to bias the differentiation of a thymocyte towards the NK1 pathway. It remains to be tested, however, whether expression of the Vix14-Jix281 TCR ix chain itself is genetically programmed in NK1 T cells, or whether it occurs randomly.
The reduced size of transgenic thymuses and the slightly different degrees of positive vs negative selection between transgenic founder lines are compatible with the view that Vcl14-Jot281 + TCIKs have an intrinsically high avidity for their CD1 ligand (8, 10, 35) . In addition, the transgenic system, by virtue of its earlier TC1K expression, may project an exaggerated picture of the normal selection process. Together with a recent report showing that a transgenic TCIK unrelated to the NK1 T cell lineage could also induce the differentiation of DN NK1 T cells, provided that the avidity for its thymic ligand was high (33), our results support the contention that expression of receptors of the NK lineage and differentiation into DN T cells can be imparted to mainstream T cell precursors during their thymic development. Support for the involvement of a distinct signaling pathway in the induction of the NK1 T cell phenotype comes from recent studies by Aberola-Ila et al. (36) who found that NK1 T cells were normally generated in the face of an ablation of the 1kas/Raf/Mek/Map kinase pathway which mediates the positive but not negative selection of mainstream thymocytes. The quality, or the avidity, of the interaction between the developing thymocyte and the ligandpresenting cell, and the resulting differences in signaling, may therefore influence the functional differentiation of thymocytes, as previously suggested in models of positive selection with agonist and antagonist ligands in vitro (37, 38) . Altogether, these results raise the intriguing possibility that the interaction between CDl-expressing cortical thymocytes and Vet 14-Jo~281 TCR-expressing thymocytes activates a distinct signaling pathway that induces downmodulation of CD8 as well as induction of NK receptors, particularly those that may dampen TC1K-mediated signaling (39) , thus allowing cells to escape negative selection.
An important property of CD4 NK1 T cells, that of rapidly releasing IL-4 on TC1K engagement, is also conferred to transgenic CD4 cells, resulting in the secretion of a markedly biased Th2 cytokine profile upon primary polyclonal stimulation in vitro and in vivo. The increased baseline levels of IgG1 and IgE Ig isotypes in Vod4-Jot281 transgenic mice therefore further indicate that NK1 T cells play a physiological role in regulating the Thl vs Th2 differentiation of immune responses.
On the other hand, it is also remarkable that, in the face of a prodigious increase in potentially available IL-4 at the outset of immune responses, Vel14-J0~281 transgenics conserve normal levels of other isotypes, in particular the Thlcontrolled lgG2a. This finding suggests that there exist immune responses, presumably those in which CD1 is not induced, where NK1 T cells are simply not recruited, or perhaps even in which they are inactivated by IL-12, as was recently documented in Listeria monocytogenes infection (40) . Indeed, preliminary experiments have shown that immunization ofVell4-Jo~281 transgenic mice with KLH and RIBI adjuvant (which includes mycolic acid and lipid A) induces antigen-specific T ceils that produce IL-4 and IFN-~/ in amounts similar to those of normal mice (not shown). We also found that Vod4-Jo~281 B6 transgenics recovered from Leishmania major infection with virtually the same kinetics as nontransgenic littermates (Scott, P., and A. Bendelac, unpublished results).
Although the range of conditions in which NK1 T cells are recruited to drive the differentiation of helper cells remains to be determined, the fact that NK1 T cells are autoreactive to CD1 and that they have been shown to mediate Th2 help for B cells upon anti-IgD injection, suggests that they may specialize in providing rapid help in a nonantigen-specific way. The induction of CD1, for example, may serve as a clue that triggers NK1 T cells, bypassing the need for associative recognition of antigen by classic T helper cells, thus providing a jump start for the effector response. Future challenges will be to elucidate the precise cellular and molecular pathways that drive the differentiation ofNK1 T cells in the thymus, and their recruitment in the course of immune responses.
